Northwest Biotherapeutics (NWBO) is suing Citadel Securities, Susquehanna International, and other names on the Street for manipulating its share price via illegal trades, according to the Wall Street Journal.
The biotechnology company has accused market-making firms of ‘spoofing’ the order book (a flurry of orders that are canceled immediately) which led to a decline in its share price.
NWBO shares have gained nearly 10.6% year-to-date.
Read full Disclosure
